Therapeutic antibody against phosphorylcholine preserves coronary function and attenuates vascular F-18-FDG uptake in atherosclerotic mice
- Stahle, M.
- Silvola, J.M.U.
- Hellberg, S.
- Vries, M. de
- Quax, P.H.A.
- Kroon, J.
- Rinne, P.
- Jong, A. de
- Liljenback, H.
- Savisto, N.
- Wickman, A.
- Stroes, E.S.G.
- Yla-Herttuala, S.
- Saukko, P.
- Abrahamsson, T.
- Pettersson, K.
- Knuuti, J.
- Roivainen, A.
- Saraste, A.
DOIAbstract
This study showed that treatment with a therapeutic monoclonal immunoglobutin-G1 antibody against phosphorylcholine on oxidized phospholipids preserves coronary flow reserve and attenuates atherosclerotic inflammation as determined by the uptake of F-18-fluorodeoxyglucose in atherosclerotic mice. The noninvasive imaging techniques represent translational tools to assess the efficacy of phosphorylcholine-targeted therapy on coronary artery function and atherosclerosis in clinical studies. (C) 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation
Add to ORKG